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Etiologies and characteristics of children with chief 
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Original article
Purpose: Short stature is a very common reason for visits to pediatric endocrine 
clinics. It could be the first sign of an underlying disease. The purpose of this study 
is to investigate the etiologies and general characteristics of subjects who visited an 
outpatient clinic due to short stature. 
Methods: We retrospectively reviewed the medical records of 3,371 patients who 
visited Severance Children’s Hospital with the chief complaint of short stature from 
2010 to 2012. Medical history, auxological data, and laboratory tests including 
bone age were collected and analyzed. Chromosome studies or combined pituitary 
function tests were performed if needed. 
Results: Approximately 89.4% of the subjects with the chief complaint of short 
stature who visited the outpatient clinic were of normal height, and only 10.6% 
of subjects were identified as having short stature. Of the subject of short stature, 
44.7% were classified as having normal variant short stature; that is, familial short 
stature (23.0%), constitutional delay in growth (17.7%), and mixed form (3.9%). 
Pathological short stature was found in 193 subjects (54.2%). Among pathological 
short stature, most common etiology was growth hormone deficiency (GHD) 
(38.9%).
Conclusion: A majority of children had a normal height. Among children with 
short stature, pathological short stature and normal variants occupied a similar 
percentage. GHD was the most common cause of pathological short stature and 
found in about 20% of the children with short stature. In pathological short stature, 
the height, height velocity, and IGF-1 level were lower than in normal variants.
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Introduction
Short stature is defined as a height below the third percentile or more than two standard 
deviations below the corresponding mean height for those of the same age, sex, and race. Short 
stature is one of the most common causes of referral to a pediatric endocrinologist. In fact, a 
large number of children have visited pediatric endocrinology clinic due to short stature. This 
trend is based on the belief that tall men are associated with the qualities expected of successful 
people1). Previous studies reported that physical height and self-esteem correlated significantly, 
therefore, those in high-status jobs are generally believed to be taller than those in low-status 
jobs2). Moreover, many reports indicated that children with short stature were academically 
and socially handicapped2-4). In contrast, other studies suggested that the psychological 
adaptation of individuals who were shorter than average was largely indistinguishable from 
that of others5,6). Despite there is no evidence that short stature is associated with psychosocial 
stress, psychological adaption, or academic performance, social stereotype of height, such as 
positive attributes being linked to tallness and negative attributes to shortness, still exist. Such 
popular stereotypical concepts about height in our society lead to hospital visits for short 
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stature in children7). 
Short stature may be the first clinical manifestation of an 
underlying pathological disease, such as growth hormone 
deficiency (GHD), chronic diseases, or clinically defined 
syndromes; thus, a precise evaluation of short stature is crucial. 
Although most children with short stature are assessed as 
being healthy even after evaluation, careful monitoring of 
growth status (e.g., measurement of height, weight, and growth 
velocity) over time is essential for child healthcare. Short 
stature is a result of various etiologies, which are categorized as 
pathological causes and normal variants. Normal variant short 
stature consists of familial short stature (FSS) and constitutional 
growth delay (CGD), while pathological causes are subdivided 
into endocrine diseases, clinically defined syndromes, chronic 
diseases, metabolic diseases and others8). Recently, clinicians 
have classified normal variant short stature as one type of 
idiopathic short stature (ISS), of which a diagnosis can be made 
after excluding the evidence of systemic, endocrine, nutritional, 
or chromosomal abnormalities. In addition, proper classification 
and precise diagnosis of short stature are essential to determine 
whether growth hormone (GH) treatment is needed or not. 
The aim of this study is to determine the etiological profile 
and distribution of the patients who visited an outpatient clinic 
to evaluate short stature.  
Materials and methods
1. Subjects
This study is based on the retrospective analysis of the data 
of 3,664 children who were evaluated for short stature at the 
Department of Pediatrics, Severance Children’s Hospital, 
Yonsei University College of Medicine, from January 2010 to 
December 2012. Patients who had a follow-up period less than 
1 year were excluded. Accordingly, 293 patients were excluded 
and 3,371 patients were analyzed. 
2. Methods
Short stature was defined as a height below the third 
percentile for the corresponding age and gender in a Korean 
growth chart that was revised in 2007, and etiological categori-
zation was based on Ranke MB's classification8). We collected 
data on the patients’ medical history (age, sex, intrauterine 
period, birth weight, yearly growth rate (YGR), midparental 
height (MPH), medication history, admission history, and 
outpatient history), physical findings (height, weight, upper/
lower ratio, Tanner staging, and any abnormal findings), and 
laboratory tests. Primary screening tests including complete 
blood count, routine chemistry, T3, free T4, thyroid-stimulating 
hormone, insulin-like growth factor-I (IGF-I), insulin-like 
growth factor binding protein-3 (IGFBP-3), and urine analysis 
were performed. Bone age was estimated through left hand 
X-rays using the Greulich-Pyle method9) performed by the same 
observer. Predicted adult height (PAH) was estimated using the 
Bayley-Pinneau method10). In subjects whose heights was below 
the third percentile for the same age and sex and growth velocity 
was attenuated, combined pituitary function tests and brain 
magnetic resonance imagings were performed. Additionally, 
chromosome studies were done in female patients with short 
stature below the third percentile.
FSS was attributed to a patient with a normal birth height 
and weight, a MPH below tenth percentile, a normal YGR, and 
a bone age appropriate for their chronologic age. CGD was 
attributed to a patient with a normal birth height and weight, a 
MPH above tenth percentile, a normal YGR, and a delayed bone 
age one to two years. GHD attributed to a patient whose GH 
levels were less than 10 ng/mL after stimulation in two kinds of 
GH provocation tests, such as insulin tolerance test and L-dopa 
test8). Diagnosis of ISS was made after evidence of systemic, 
endocrine, nutritional or genetic abnormalities was not found.
3. Statistical analysis
Statistical analysis of the results was performed using IBM 
SPSS Statistics ver. 20.0 (IBM Co., Armonk, NY, USA). All data 
was expressed as mean±standard deviation. Chi-square and 
t-test distributions were performed for between-pairs com-
parisons, and comparisons among groups were performed using 
analyses of variances. Differences were regarded as significant 
when P<0.05.
Results
1. Frequency of children with chief complaints of short 
   stature
Among 3,371 subjects, 3,015 (89.4%) had a normal height 
and 356 (10.6%) had short stature below the third percentile 
in the growth chart (Table 1). Of those with short stature, 159 
(44.7%) were normal variants, 193 (54.2%) had pathological 
short stature, and 4 patients (1.1%) were uncategorized (Table 2). 
In the group of normal variants, there were 82 patients (23.0%) 
with FSS, 63 patients (17.7%) with CGD, and 14 patients (3.9%) 
who had both. In the uncategorized group, 2 patients were 
suspected of having GHD because of attenuated growth and 
low levels of IGF-I and IGFBP-3 (patient 1: –0.6 SDS IGF-I, –1.3 
SDS IGFBP-3; patient 2: –0.5 SDS IGF-I, –1.1 SDS IGFBP-3). 
While follow-ups without GH provocation tests, these cases 
were missing. 
Fig. 1 showed the distribution curve of the children’s height. 
Table 1. Frequency of children with chief complaints of short 
stature
Category No. of subjects (%)
Normal (>3 percentile) 3,015 (89.4)
Short stature (<3 percentile)  356 (10.6)
Total 3,371 (100)
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Of the children with normal heights, 1,196 (39.7%) had a SDS of 
–2 to –1, and 1,015 (33.7%) had a SDS of –1 to 0. These findings 
suggest that most children with normal heights (73.3%) who 
visited the hospital due to short stature had heights less than the 
average, with a SDS of –2 to 0. 
2. Frequency of the various diagnoses of the children with
    pathological short stature
Of the patients with pathological short stature, the most 
common cause was GHD (38.9%), followed by ISS (23.2%), 
small for gestational age (11.3%), and Turner syndrome (9.3%) 
(Table 3). The others (12.4%) were considered to have diverse 
etiologies, such as clinically defined syndromes, skeletal 
dysplasias, metabolic disorders, and chronic renal failures. GHD 
was diagnosed in approximately 20% of children with short 
stature.
3. Causes of short stature in patients with GHD 
Of  the patients with GHD, 21 patients (28.0%) had 
morphological brain abnormalities or underlying diseases, and 
54 patients (72.0%) had no specific brain lesions (Table 4). Of 
the 21 patients with organic GHD, Rathke’s cleft cyst (9.3%) and 
hypoxic brain damage (9.3%) were the most common causes, 
Table 2. Frequency of the various diagnoses of the children with 
short stature
Diagnosis No. of subjects (%)
Normal variants 159 (44.7)
Familial short stature        82 (23.0)
CGD 63 (17.7)
Familial short stature and CGD 14 (3.9)
Pathological short stature 193 (54.2)
Uncategorized 4 (1.1)
Total 356 (100)
CGD, constitutional delay in growth.
Table 3. Frequency of the various diagnoses of the children with 
pathological short stature 
Diagnosis No. of subjects (%)
Growth hormone deficiency   75 (38.9)
Idiopathic short stature   45 (23.2)
Small for gestational age   22 (11.3)
Turner syndrome   18 (9.3)
Congenital heart disease     6 (3.1)
Noonan syndrome      4 (2.1)
Anemia     4 (2.1)
Hypochondroplasia     3 (1.5)
Rickets     3 (1.5)
Russel-Silver syndrome     2 (1.0)
Cancer     2 (1.0)
Precocious puberty     2 (1.0)
Scoliosis     1 (0.5)
Skeletal dysplasia     1 (0.5)
Mitochondrial cytopathy     1 (0.5)
Chronic renal failure     1 (0.5)
Hypothyroidism     1 (0.5)
DM     1 (05)
Choledochal cyst     1 (0.5)
Total 193 (100)
DM, diabetes mellitus.
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Fig. 1. Distribution of height standard deviation score (SDS) of the children with chief complaint of short stature.
Table 4. Causes of short stature in patients with growth hormone 
deficiency (GHD)
Diagnosis No. of subjects (%)
Idiopathic GHD   54 (72.0)
Organic GHD   21 (28.0)
Rathke’s cleft cyst     7 (9.3)
Hypoxic brain damage     7 (9.3)
Small size of pituitary gland     3 (4.0)
Pituitary tumor     2 (2.7)
Microcephaly     1 (1.3)
Arnold chiari malformation     1 (1.3)
Total   75 (100)
GHD, growth hormone deficiency.
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followed by small pituitary glands (4.0%), pituitary tumors 
(2.7%), microcephaly (1.3%), and Arnold-Chiari malformation 
(1.3%).
4. Auxological characteristics of the patients with FSS, CGD 
   and pathological short stature
Children with FSS showed the least bone age (BA) delay, the 
lowest MPH SDS, normal growth velocity and the highest IGF-
1 level, whereas CGD children had the lowest BMI, the most 
BA delay, normal growth velocity, and the highest PAH SDS. 
Children with pathological short stature were significantly 
shorter, and had the lowest height velocity, height velocity SDS 
and IGF-I level (Table 5).
5. Frequency of the various diagnoses according to severity 
   of short stature
The patients were categorized according to the severity of 
their short stature in two groups, that is those with a height SDS 
of ≤–3 and those with a height SDS of >–3. A total of 101 (43 
boys and 58 girls) (28.4%) presented very short stature; that is, 
their height SDS was ≤–3, and 255 patients (129 boys and 126 
girls) (71.6%) presented less severe short stature; that is, a height 
SDS of >–3. Even though it was not significant statistically, 
the most common diagnosis in the very short children was 
GHD (20.8%), whereas the most common diagnosis in the less 
severely short children was FSS (25.1%). CGD is more common 
in less severely short children than in very short children, while 
clinically defined syndromes are significantly more common in 
very short children than in less severely short children (Table 6).
Discussion
In this study, we presented auxological characteristics and 
distributions of various diagnoses of short stature in children 
who visited a pediatric endocrinology clinic due to short stature 
in a 3-year period. The majority of the children who visited the 
outpatient clinic had normal heights, while only 10.6% of the 
children were identified as having short stature. The percentage 
of patients with normal heights in this study (89.4%) was higher 
than in a previous Korean report by Kim and Yoo11) (62.2%). 
This finding suggests that more children who visited hospital 
with normal heights, which may suggest that the popular 
stereotypical preference for tall statures has intensified, or simply 
reflect the differences in hospital characteristics or locations, 
even though both involved the same tertiary hospital. In fact, 
76.1% of the patients with normal heights were below the 50th 
percentile, suggesting that shorter patients within the normal 
range tended to visit outpatient clinics more often. 
In the short stature group in our study, the percentage of 
patients with pathological short stature (54.2%) was higher 
than that of patients with normal variants (44.7%). Previous 
studies11-15) have demonstrated that most children with short 
stature are normal variants, and may constitute more than 
65% of short stature children. The reason for the discrepancy 
between this study and others is unclear, however, there is a 
Table 6. Diagnosis according to severity of short stature
Diagnosis Height SDS≤–3 Height SDS>–3 P-value
Familial short stature 18 (17.8) 64 (25.1) 0.142
CGD 9 (8.9) 54 (21.2) 0.006
Familial short stature + CGD 6 (5.9) 8 (3.1) 0.220
Growth hormone deficiency 21 (20.8) 54 (21.2) 0.936
Idiopathic short stature 15 (14.9) 30 (11.8) 0.429
Clinically defined syndromes 15 (14.9) 9 (3.5) <0.001
Small for gestational age 8 (7.9) 14 (5.5) 0.391
Disorders in specific systems 2 (2.0) 12 (4.7) 0.365
Skeletal dysplasias 4 (4.0) 4 (1.6) 0.230
Endocrine disorders
  (non-GHD)
1 (1.0) 3 (1.2) 1.000
Others 2 (2.0) 3 (1.2) 0.625
Total 101 (100) 255 (100)
Values are presented as number (%).
SDS, standard deviation score; CGD, constitutional delay in 
growth; GHD, growth hormone deficiency.
Table 5. Auxological characteristics of children with normal variant and pathological short stature
Variable FSS (n=82) CGD (n=63) Pathologic SS (n=193) P-value
Age (yr) 10.21±5.28 8.23±3.63 7.42±3.90 <0.001
Sex, male/female 24/58 38/25 103/90 <0.001
Height SDS –2.66±0.58 –2.51±0.45 –2.92±0.85 <0.001
Body mass index (kg/m2) 18.01±3.39 15.75±2.64 16.33±2.86 <0.001
Bone age delay (yr) 0.50±0.88 1.80±0.72 1.73±3.12 <0.001
Height velocity (cm/yr) 4.47±2.51 4.78±1.27 3.92±1.83 0.006
Height velocity SDS 0.07±1.70 –0.32±1.49 –1.14±1.70 <0.001
MPH SDS –2.09±0.39 –0.57±0.64 –0.67±0.97 <0.001
PAH SDS –3.38±5.40 –0.78±1.13 –2.56±0.37 0.004
IGF-I (ng/mL) 208.38±17.97 161.30±82.92 135.23±83.21 <0.001
IGFBP-3 (μg/mL) 2.24±0.58 2.15±0.65 2.02±0.70 0.086
Values are presented as mean±standard deviation. 
FSS, familial short stature; CGD, constitutional delay in growth; SS, short stature; SDS, standard deviation score; MPH, midparental height; 
PAH, predicted adult height.
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possibility of referral bias in tertiary hospitals.
In the pathological short stature group in this study, GHD 
was the most common cause of short stature (38.9%), followed 
by ISS (23.2%), small for gestational age (11.3%), Turner 
syndrome (9.3%), and others. High prevalence of GHD as a 
cause of short stature has been reported in almost all previous 
studies. In our study, GHD was diagnosed in approximately 
20% of the children with short stature, which is similar to 
the 22.8% in Zargar et al.15). and the 23.4% in Moayeri and 
Aghighi16). In contrast, other studies11-13) showed GHD occurred 
in 11.1%–13.0% of short stature cases, which is less than in our 
study. Even though most GHD is idiopathic, 28% of GHD cases 
revealed organic abnormalities, such as Rathke’s cleft cysts17), 
small-sized pituitary glands, pituitary tumors or other anatomic 
abnormalities, suggesting that comprehensive evaluations for 
combined morbidities or anatomical abnormalities are required 
for patients with GHD. 
As expected, the comparison of the auxological characteristics 
of FSS, CGD, and pathological short stature confirmed these 
findings: (1) The height velocity and height velocity SDS are 
lowest in pathological short stature; (2) the bone age delay 
is lowest in FSS; (3) the MPH SDS is lowest in FSS; (4) the 
PAH SDS is normal in CGD; (5) the IGF-I level is lowest in 
pathological short stature. 
The heights of those with pathological short stature were 
shorter than those for normal variants; therefore, physicians 
should evaluate the possibility of pathologic diseases more 
carefully when the patients have lower height SDS within the 
short stature group. In our study, children with a very short 
stature (that is, height SDSs of ≤–3) were more likely to have 
pathological short stature. Normal variants were present in 
about 49.4% of children with less severe short stature (that 
is, height SDSs of >–3), while in only 32.6% of the very short 
children. These results are comparable with a previous report by 
Papadimitriou et al.13) that also showed there were more normal 
variants in less severe groups than in very short stature ones.  
In conclusion, a careful monitoring of growth and a precise 
evaluation of short stature are very important to discover 
the pathologic causes and determine whether GH treatment 
is needed18). Our data shows that only 10.6% of the children 
with chief complaint of short stature were identified as having 
short stature. Approximately 54% of children of short stature 
presented pathological short stature, whereas normal variants 
were diagnosed in about 45% of the short children. GHD was 
the most common cause of pathological short stature, and was 
found in approximately 20% of the children with short stature.
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